SIU 2017: Combined Clinical Parameters and Multiparametric MRI for Advanced Risk Modeling of Prostate Cancer - Patient-Tailored Risk Stratification Can Reduce Unnecessary Biopsies

Lisbon, Portugal (UroToday.com) Multiparametric MRI (mpMRI) is gaining widespread acceptance in prostate cancer (PC) diagnosis and improves significant PC (Gleason score >3+4) detection. Decision-making based on European Randomized study of Screening for PC (ERSPC) risk-calculator (RC) parameters may overcome PSA-limitations. The authors added pre-biopsy mpMRI to ERSPC-RC parameters and developed risk models (RM) to predict individual significant PC-risk for biopsy-naive men and men after a previous biopsy.

Clinical parameters of 1159 men who underwent mpMRI prior to MRI/TRUS-fusion-biopsy between 2012 and 2015 were retrospectively analyzed. Multivariable regression analyses were used to determine significant PC-predictors for RM-development. The prediction-performance was compared to ERSPC-RCs, RCs refitted on our cohort, PI-RADSv1.0 and ERSPC-RC plus PI-RADSv1.0 using receiver-operating-characteristics (ROC). Discrimination and calibration of the RM, as well as net decision and reduction curve analyses were evaluated based on resampling methods.

PSA, prostate volume, digital-rectal examination and PI-RADS were significant predictors of significant prostate cancer and included in the RMs together with age. ROC area-under-the-curve (AUC) of the RM for biopsy-naïve men was comparable to ERSPC-RC plus PI-RADSv1.0 (0.83 versus 0.84) but larger compared to ERSPC-RC (0.81), the refitted RC3 (0.80) and PIRADS (0.76). For post-biopsy men, the novel RM's discrimination (0.81) was higher, compared to PIRADS (0.78), ERSPC-RC (0.66), refitted RC (0.76) and ERSPC-RC plus PI-RADSv1.0 (0,78). Both RMs benefits exceeded that of ERSPC-RCs and PI-RADS in the decision which patient to biopsy and enabled the highest reduction rate of unnecessary biopsies.

These novel RMs, incorporating clinical parameters and PI-RADS, performed significantly better compared to RMs without PI-RADS and provide measurable benefit in making the decision when to biopsy men with suspected PC. For biopsy-naive patients both our RM and ERSPC-RC plus PIRADSv1.0 exceeded the prediction-performance when compared to clinical parameters alone.     


Presented by: Radtke JP
Affiliation:  Dept. of Urology, Heidelberg University Hospital, Heidelberg, Germany

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal





E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe